Heikman Pertti Kalevi, Muhonen Leea Hellevi, Ojanperä Ilkka Antero
University of Helsinki and Helsinki University Central Hospital, Psychiatry, P.O. Box 22, Välskärinkatu 12 A, FI-00014, Helsinki, Finland.
University of Helsinki, Forensic Medicine, P.O. Box 40, Kytösuontie 11, FI-00014, Helsinki, Finland.
BMC Psychiatry. 2017 Jul 6;17(1):245. doi: 10.1186/s12888-017-1415-y.
Polydrug abuse is a known problem among opioid-dependent patients receiving opioid maintenance treatment (OMT). However, improved laboratory diagnostics is required to reveal polydrug abuse in its current scope. Furthermore, there are few studies focusing on the relationship between polydrug abuse and adequacy of the dose of OMT medicine. This study aimed to evaluate the polydrug abuse among opioid-dependent patients receiving OMT with inadequate (Group IA) and adequate (Group A) doses of OMT medicine as experienced by the patients. Craving for opioids and withdrawal symptoms were evaluated as indicators of the adequacy rating.
This is a retrospective register-based study of 60 OMT patients on either methadone or sublingual buprenorphine/naloxone medication, whose polydrug abuse was studied from urine samples by means of a comprehensive high-resolution mass spectrometry method.
Inadequate doses of the OMT medicines were associated with higher subjective withdrawal scores and craving for opioids. Six groups of abused substances (benzodiazepines, amphetamines, opioids, cannabis, new psychoactive substances, and non-prescribed psychotropic medicines) were found among OMT patients. Group IA patients showed significantly more abuse of benzodiazepines and amphetamines than the Group A patients. All the new psychoactive substances and most of the non-prescribed psychotropic medicines were detected from the Group IA patients. There was no difference in the doses of the OMT medicine between Groups IA and A patients.
Polydrug abuse, detected by definitive laboratory methods, was widespread and more common among Group IA than Group A patients, emphasizing the requirement for individual OMT medicine dose adjustment.
在接受阿片类药物维持治疗(OMT)的阿片类药物依赖患者中,多药滥用是一个已知问题。然而,需要改进实验室诊断方法以揭示当前范围内的多药滥用情况。此外,很少有研究关注多药滥用与OMT药物剂量充足性之间的关系。本研究旨在评估接受OMT治疗的阿片类药物依赖患者中,患者所经历的OMT药物剂量不足(IA组)和充足(A组)情况下的多药滥用情况。将对阿片类药物的渴望和戒断症状作为充足性评级的指标进行评估。
这是一项基于登记的回顾性研究,研究对象为60名接受美沙酮或舌下含服丁丙诺啡/纳洛酮治疗的OMT患者,通过综合高分辨率质谱法从尿液样本中研究其多药滥用情况。
OMT药物剂量不足与更高的主观戒断评分和对阿片类药物的渴望有关。在OMT患者中发现了六类滥用物质(苯二氮䓬类、苯丙胺类、阿片类、大麻、新型精神活性物质和非处方精神药物)。IA组患者比A组患者表现出明显更多的苯二氮䓬类和苯丙胺类药物滥用。所有新型精神活性物质和大多数非处方精神药物均在IA组患者中检测到。IA组和A组患者之间的OMT药物剂量没有差异。
通过明确的实验室方法检测到的多药滥用情况普遍存在,且在IA组患者中比A组患者更常见,这强调了对个体OMT药物剂量调整的需求。